MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Gossamer Bio Inc

Suletud

SektorTervishoid

1.23 0.82

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.23

Max

1.24

Põhinäitajad

By Trading Economics

Sissetulek

-3.6M

-37M

Müük

510K

9.9M

Aktsiakasum

-0.16

Kasumimarginaal

-370.492

Töötajad

144

EBITDA

-1.9M

-34M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+605.65% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

8. aug 2025

Turustatistika

By TradingEconomics

Turukapital

32M

282M

Eelmine avamishind

0.41

Eelmine sulgemishind

1.23

Uudiste sentiment

By Acuity

67%

33%

318 / 375 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. juuli 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4. juuli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. juuli 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4. juuli 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

4. juuli 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4. juuli 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. juuli 2025, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4. juuli 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4. juuli 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

4. juuli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4. juuli 2025, 15:57 UTC

Market Talk

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4. juuli 2025, 15:49 UTC

Market Talk

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4. juuli 2025, 15:49 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4. juuli 2025, 15:49 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4. juuli 2025, 15:49 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole Received All Required Authorizations

4. juuli 2025, 15:48 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4. juuli 2025, 15:47 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole: Agreement Was Announced on Dec. 19

4. juuli 2025, 15:47 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4. juuli 2025, 15:46 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4. juuli 2025, 14:30 UTC

Omandamised, ülevõtmised, äriostud

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4. juuli 2025, 13:53 UTC

Market Talk

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4. juuli 2025, 13:41 UTC

Market Talk

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4. juuli 2025, 13:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

4. juuli 2025, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4. juuli 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4. juuli 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4. juuli 2025, 12:30 UTC

Market Talk

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4. juuli 2025, 12:15 UTC

Market Talk

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4. juuli 2025, 12:13 UTC

Market Talk

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4. juuli 2025, 12:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

605.65% tõus

12 kuu keskmine prognoos

Keskmine 8.75 USD  605.65%

Kõrge 15 USD

Madal 4 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

5

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

318 / 375 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.